ANCA-associated vasculitis: From bench research to novel treatments

Nature Reviews Nephrology

Volumn 5, Issue 5, 2009, Pages 278-286

  Pallan, Lalit ^a   Savage, Caroline O ^a   Harper, Lorraine ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; ABATACEPT; ALEMTUZUMAB; ATLIZUMAB; AZATHIOPRINE; CD20 ANTIBODY; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; ETANERCEPT; IMATINIB; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE SYK INHIBITOR; RITUXIMAB; STEROID; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY; MONOCLONAL ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ANCA ASSOCIATED VASCULITIS; B LYMPHOCYTE; CELL FUNCTION; CELL THERAPY; CLINICAL TRIAL; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GLOMERULONEPHRITIS; GRANULOMATOUS INFLAMMATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKOPENIA; LOW DRUG DOSE; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TREATMENT FAILURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEGENER GRANULOMATOSIS; IMMUNOLOGY; KIDNEY FAILURE; VASCULITIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE; VASCULITIS;

EID: 67650360201     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2009.45     Document Type: Review

References (104)

1. Savage, C. O. S., Harper, L. & Adu, D. Primary systemic vasculitis. Lancet 349, 553-558 (1997).
2. Watts, R. A., Lane, S. E., Bentham, G. & Scott, D. G. epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum. 43, 414-419 (2000).
3. Mukhtyar, C. et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the european League Against rheumatism systemic vasculitis task force. Ann. Rheum. Dis. 67, 1004-1010 (2008).
4. Watts, R. et al. Geoepidemiology of systemic vasculitis: comparison of the incidence in two regions of europe. Ann. Rheum. Dis. 60, 170-172 (2001).
5. Mukhtyar, C. et al. eULAr recommendations for the management of primary small and medium vessel vasculitis. Ann. Rheum. Dis. doi:10.1136/ard.2008.088096 (2008).
6. De Groot, K., Adu, D. & Savage, C. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol. Dial. Transplant. 16, 2018-2027 (2001).
7. Jayne, D. R. et al. randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J. Am. Soc. Nephrol. 18, 2180-2188 (2007).
8. De Groot, K. et al. randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 52, 2461-2469 (2005).
9. Jayne, D. et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N. Engl. J. Med. 349, 36-44 (2003). (Pubitemid 36765101)
10. Metzler, C., Fink, C., Lamprecht, P., Gross, W. L. & Reinhold-Keller, E. Maintenance of remission with leflunomide in wegener's granulomatosis. Rheumatology (Oxford) 43, 315-320 (2004).
11. Langford, C. A., Talar-williams, C. & sneller, M. C. Mycophenolate mofetil for remission maintenance in the treatment of wegener's granulomatosis. Arthritis Rheum. 51, 278-283 (2004).
12. Flossmann, O. & Jayne, D. R. Maintaining remission in a patient with vasculitis. Nat. Clin. Pract. Rheumatol. 4, 499-504 (2008).
13. Booth, A. D. et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am. J. Kidney Dis. 41, 776-784 (2003).
14. Azathioprine; cyclophosphamide; prednisolone in Therapeutic Drugs (ed. Dollery, C.) p. A181-A184; C366-C372; P199-P220 (London, Churchill Livingstone, 1991).
15. De Leeuw, K. et al. Accelerated atherosclerosis in patients with wegener's granulomatosis. Ann. Rheum. Dis. 64, 753-759 (2005). (Pubitemid 40559304)
16. Hogan, S. L. et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann. Intern. Med. 143, 621-631 (2005).
17. Pagnoux, C. et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum. 58, 2908-2918 (2008).
18. Hoffman, G. S. et al. wegener's granulomatosis: an analysis of 158 patients. Ann. Intern. Med. 116, 488-498 (1992).
19. Guillevin, L. et al. A prospective, multi-center randomized trial comparing steroids and pulse cyclophosphomide versus steroids and oral cyclophosphomide in the treatment of generalised wegener's granulomatosis. Arthritis Rheum. 40, 2187-2198 (1997).
20. stegeman, C. A., Cohen Tervaert, J. w., Manson, w. L. & Kallenberg, C. G. M. Persistent nasal carriage of Staphylococcus aureus and relapse rate of wegener's granulomatosis. Presented at the 4th international workshop on ANCA, May 28-30, Lübeck, Germany (1992).
21. Hagen, E. et al. Diagnostic value of standardized assays for antineutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. Kidney Int. 53, 743-753 (1998).
22. Boomsma, M. M. et al. Prediction of relapses in wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum. 43, 2025-2033 (2000).
23. Bansal, P. J. & Tobin, M. C. Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. Ann. Allergy Asthma Immunol. 93, 398-401 (2004).
24. Xiao, H. et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J. Clin. Invest. 110, 955-963 (2002).
25. Xiao, H. et al. The role of neutrophils in the induction of glomerulonephritis by antimyeloperoxidase antibodies. Am. J. Pathol. 167, 39-45 (2005).
26. Schreiber, A., Xiao, H., Falk, R. J. & Jennette, J. C. Bone marrow-derived cells are sufficient and necessary targets to mediate glomerulonephritis and vasculitis induced by anti-myeloperoxidase antibodies. J. Am. Soc. Nephrol. 17, 3355-3364 (2006).
27. Little, M. A. et al. Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood 106, 2050-2058 (2005).
28. Harper, L., Cockwell, P., Adu, D. & savage, C. Neutrophil priming and apoptosis in ANCAassociated vasculitis. Kidney Int. 59, 1729-1738 (2001).
29. Muller Kubold, A., Mesander, G., Stegeman, C., Kallenberg, C. & Cohen Tervaert, J. Are circulating neutrophils intravascularly activated in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides? Clin. Exp. Immunol. 114, 491-499 (1998).
30. Huugen, D. et al. Aggravation of antimyeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-á. Am. J. Pathol. 167, 47-58 (2005).
31. Falk, R. J., Terrell, R. S., Charles, L. A. & Jennette, J. C. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc. Natl Acad. Sci. USA 87, 4115-4119 (1990).
32. Condliffe, A. M., Chilvers, E. R., Haslett, C. & Dransfield, I. Priming differentially regulates neutrophil adhesion molecule expression/ function. Immunology 89, 105-111 (1996).
33. williams, J. M. et al. Activation of the Gi heterotrimeric G protein by ANCA igG F(ab')2 fragments is necessary but not sufficient to stimulate the recruitment of those downstream mediators used by intact ANCA igG. J. Am. Soc. Nephrol. 14, 661-669 (2003).
34. Hewins, P., Williams, J. M., Wakelam, M. J. & Savage, C. O. Activation of syk in neutrophils by antineutrophil cytoplasm antibodies occurs via Fcã receptors and CD18. J. Am. Soc. Nephrol. 15, 796-808 (2004).
35. Radford, D., Lord, J. & Savage, C. The activation of the neutrophil respiratory burst by antineutrophil cytoplasm autoantibody (ANCA) from patients with systemic vasculitis requires tyrosine kinases and protein kinase C activation. Clin. Exp. Immunol. 118, 171-179 (1999).
36. Ben-Smith, A., Dove, S., Martin, A., wakelam, M. & Savage, C. Anti-neutrophil cytoplasmic autoantibodies from patients with systemic vasculitis activate neutrophils via distinct signalling cascades compared to conventional Fcã receptor ligation. Blood 981, 1448-1455 (2001).
37. Williams, J. M. & Savage, C. O. Characterization of the regulation and functional consequences of p21ras activation in neutrophils by antineutrophil cytoplasm antibodies. J. Am. Soc. Nephrol. 16, 90-96 (2005).
38. Reumaux, D., Kuijpers, T. W., Hordijk, P. L., Duthilleul, P. & Roos, D. involvement of Fcã receptors and â2 integrins in neutrophil activation by anti-proteinase-3 or antimyeloperoxidase antibodies. Clin. Exp. Immunol. 134, 344-350 (2003).
39. Savage, C. O., Harper, L. & Holland, M. New findings in pathogenesis of antineutrophil cytoplasm antibody-associated vasculitis. Curr. Opin. Rheumatol. 14, 15-22 (2002).
40. Nolan, S. L. et al. Mechanisms of ANCAmediated leukocyte-endothelial cell interactions in vivo. J. Am. Soc. Nephrol. 19, 973-984 (2008).
41. Lamprecht, P. Off balance: T-cells in antineutrophil cytoplasmic antibody (ANCA)- associated vasculitides. Clin. Exp. Immunol. 141, 201-210 (2005).
42. Giscombe, R., wang, X. B., Kakoulidou, M. & Lefvert, A. K. Characterization of the expanded T-cell populations in patients with wegener's granulomatosis. J. Intern. Med. 260, 224-230 (2006).
43. Marinaki, S. et al. Abnormalities of CD4 T cell subpopulations in ANCA-associated vasculitis. Clin. Exp. Immunol. 140, 181-191 (2005).
44. Abdulahad, W. H. et al. Functional defect of circulating regulatory CD4+ T cells in patients with wegener's granulomatosis in remission. Arthritis Rheum. 56, 2080-2091 (2007).
45. Thewissen, M. et al. CD4+CD28null T cells in autoimmune disease: pathogenic features and decreased susceptibility to immunoregulation. J. Immunol. 179, 6514-6523 (2007).
46. Voswinkel, J. et al. B lymphocyte maturation in wegener's granulomatosis: a comparative analysis of vH genes from endonasal lesions. Ann. Rheum. Dis. 65, 859-864 (2006).
47. Hooke, D., Gee, D. & Atkins, R. Leukocyte analysis using monoclonal antibodies in glomerulonephritis. Kidney Int. 31, 964-972 (1987).
48. Popa, E. R., stegeman, C. A., Bos, N. A., Kallenberg, C. G. & Tervaert, J. w. Differential B- and T-cell activation in wegener's granulomatosis. J. Allergy Clin. Immunol. 103, 885-894 (1999).
49. Culton, D. A. et al. similar CD19 dysregulation in two autoantibody-associated autoimmune diseases suggests a shared mechanism of B-cell tolerance loss. J. Clin. Immunol. 27, 53-68 (2007).
50. Voswinkel, J., Muller, A. & Lamprecht, P. is Pr3- ANCA formation initiated in wegener's granulomatosis lesions? Granulomas as potential lymphoid tissue maintaining autoantibody production. Ann. NY Acad. Sci. 1051, 12-19 (2005).
51. Stassen, P. M., Cohen Tervaert, J. W. & Stegeman, C. A. induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann. Rheum. Dis. 66, 798-802 (2007).
52. Joy, M. S., Hogan, S. L., Jennette, J. C., Falk, R. J. & Nachman, P. H. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol. Dial. Transplant. 20, 2725-2732 (2005).
53. Hu, W. et al. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol. Dial. Transplant. 23, 1307-1312 (2008).
54. european vasculitis study Group Active Clinical Trials http://www.vasculitis.org/acttrials.htm
55. Diegel, M. L., Nadler, S. G. & Kiener, P. A. In vivo administration of 15-deoxyspergulin inhibits antigen-presenting cell stimulation of T cells and NF-êB activation. Int. Immunopharmacol. 2, 1451-1464 (2002).
56. Tepper, M. A., Nadler, S. G., esselstyn, J. M. & Sterbenz, K. G. Deoxyspergualin inhibits ê light chain expression in 70Z/3 pre-B cells by blocking lipopolysaccharide-induced NF-êB activation. J. Immunol. 155, 2427-2436 (1995).
57. Kalsch, A. I. et al. In vivo effects of cyclic administration of 15-deoxyspergualin on leucocyte function in patients with wegener's granulomatosis. Clin. Exp. Immunol. 146, 455-462 (2006).
58. Flossmann, O. et al. Deoxyspergualin in relapsing and refractory wegener's granulomatosis. Ann. Rheum. Dis. doi:10.1136/ard.2008.092429 (2008).
59. Schmitt, W. H. et al. Prolonged treatment of refractory wegener's granulomatosis with 15-deoxyspergualin: an open study in seven patients. Nephrol. Dial. Transplant. 20, 1083-1092 (2005).
60. Walsh, M. & Jayne, D. rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future. Kidney Int. 72, 676-682 (2007).
61. Ramos-Casals, M., Brito-Zeron, P., Munoz, S. & Soto, M. J. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore) 87, 345-364 (2008).
62. Yokoyama, H. et al. Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy: case report and review of the literature. Int. J. Hematol. 88, 443-447 (2008).
63. Smith, K. G., Jones, R. B., Burns, S. M. & Jayne, D. R. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum. 54, 2970-2982 (2006).
64. Ferraro, A. J., Drayson, M. T., Savage, C. O. & MacLennan, I. C. Levels of autoantibodies, unlike antibodies to all extrinsic antigen groups, fall following B cell depletion with rituximab. Eur. J. Immunol. 38, 292-298 (2008).
65. Hoyer, B. F. et al. short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/w mice. J. Exp. Med. 199, 1577-1584 (2004).
66. Cassese, G. et al. inflamed kidneys of NZB/w mice are a major site for the homeostasis of plasma cells. Eur. J. Immunol. 31, 2726-2732 (2001).
67. Taylor, R. P. & Lindorfer, M. A. immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr. Opin. Immunol. 20, 444-449 (2008).
68. Assi, L. K. et al. Tumor necrosis factor á activates release of B lymphocyte stimulator by neutrophils infiltrating the rheumatoid joint. Arthritis Rheum. 56, 1776-1786 (2007).
69. Krumbholz, M. et al. BAFF is elevated in serum of patients with wegener's granulomatosis. J. Autoimmun. 25, 298-302 (2005).
70. Ding, C. Belimumab, an anti-BLys human monoclonal antibody for potential treatment of inflammatory autoimmune diseases. Expert Opin. Biol. Ther. 8, 1805-1814 (2008).
71. Schmitt, W. H. et al. Treatment of refractory wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int. 65, 1440-1448 (2004).
72. Walsh, M., Chaudhry, A. & Jayne, D. R. Long-term follow-up of relapsing/refractory ANCA associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann. Rheum. Dis. 67, 1322-1327 (2008).
73. Sansom, D. M. & Walker, L. S. The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology. Immunol. Rev. 212, 131-148 (2006).
74. Linsley, P. S. et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1, 793-801 (1994).
75. Greene, J. L. et al. Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/ CD86 regulate T cell costimulatory interactions. J. Biol. Chem. 271, 26762-26771 (1996).
76. Zhou, Y. et al. An analysis of CTLA-4 and proinflammatory cytokine genes in wegener's granulomatosis. Arthritis Rheum. 50, 2645-2650 (2004).
77. Kremer, J. M. et al. effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 144, 865-876 (2006).
78. Kremer, J. M. et al. results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum. 58, 953-963 (2008).
79. Reynolds, J. et al. CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis. J. Clin. Invest. 105, 643-651 (2000).
80. Little, M. A. et al. Therapeutic effect of anti-TNF-á antibodies in an experimental model of anti-neutrophil cytoplasm antibodyassociated systemic vasculitis. J. Am. Soc. Nephrol. 17, 160-169 (2006).
81. Khan, S. B. et al. Antibody blockade of TNF-á reduces inflammation and scarring in experimental crescentic glomerulonephritis. Kidney Int. 67, 1812-1820 (2005).
82. Booth, A. et al. Prospective study of TNFá blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J. Am. Soc. Nephrol. 15, 717-721 (2004).
83. Stone, J. H. et al. etanercept combined with conventional treatment in wegener's granulomatosis. Arthritis Rheum. 44, 1149-1154 (2001).
84. Group, W. R. etanercept plus standard therapy for wegener's granulomatosis. N. Engl. J. Med. 352, 351-361 (2005).
85. Wung, P. K. et al. effects of glucocorticoids on weight change during the treatment of wegener's granulomatosis. Arthritis Rheum. 59, 746-753 (2008).
86. Stone, J. H. et al. solid malignancies among patients in the wegener's Granulomatosis etanercept Trial. Arthritis Rheum. 54, 1608-1618 (2006).
87. Wung, P. et al. risk factors for herpes zoster in immunocompromised patients: experience from the wegener's granulomatosis etanercept trial. Kidney Blood Press. Res. 28, 175 (2005).
88. Osterman, M. T. & Lichtenstein, G. R. Current and future anti-TNF therapy for inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 10, 195-207 (2007).
89. Nishimoto, N. et al. Long-term safety and efficacy of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the sTreAM study): evidence of safety and efficacy in a 5-year extension study. Ann. Rheum. Dis. doi:10.1136/ard.2008.092866 (2008).
90. Pine, P. R. et al. inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel syk inhibitor. Clin. Immunol. 124, 244-257 (2007).
91. Weinblatt, M. E. et al. Treatment of rheumatoid arthritis with a syk kinase inhibitor: a twelveweek, randomized, placebo-controlled trial. Arthritis Rheum. 58, 3309-3318 (2008).
92. Smith, J. et al. syk inhibitor is effective in treatment of experimental glomerulonephritis [abstract]. J. Am. Soc. Nephrol. 19, 63A (2008).
93. Kälsch, A. I. et al. imatinib mesylate, a new kid on the block for the treatment of anti-neutrophil cytoplasmic autoantibodies-associated vasculitis? Clin. Exp. Immunol. 151, 391-398 (2008).
94. Paniagua, R. T. et al. selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J. Clin. Invest. 116, 2633-2642 (2006).
95. Hirsch, e. et al. Central role for G protein-coupled phosphoinositide 3-kinase ã in inflammation. Science 287, 1049-1053 (2000).
96. Li, Z. et al. roles of PLC-â2 and -â3 and Pi3Kã in chemoattractant-mediated signal transduction. Science 287, 1046-1049 (2000).
97. Camps, M. et al. Blockade of Pi3Kã suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat. Med. 11, 936-943 (2005).
98. Barber, D. F. et al. Pi3Kã inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat. Med. 11, 933-935 (2005).
99. Clarke, H. C. et al. ras antagonist farnesylthiosalicylic acid (FTs) reduces glomerular cellular proliferation and macrophage number in rat thy-1 nephritis. J. Am. Soc. Nephrol. 14, 848-854 (2003).
100. Braun, T. & Fenaux, P. Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia. Br. J. Haematol. 141, 576-586 (2008).
101. Gratwohl, A. et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplant. 35, 869-879 (2005).
102. Daikeler, T. et al. Haematopoietic stem cell transplantation for vasculitis including Behçet's disease and polychondritis: a retrospective analysis of patients recorded in the european Bone Marrow Transplantation and european League Against rheumatism databases and a review of the literature. Ann. Rheum. Dis. 66, 202-207 (2007).
103. Statkute, L. et al. Autologous non-myeloablative haematopoietic stem cell transplantation for refractory systemic vasculitis. Ann. Rheum. Dis. 67, 991-997 (2008).
104. Kotter, I., Daikeler, T., Amberger, C., Tyndall, A. & Kanz, L. Autologous stem cell transplantation of treatment-resistant systemic vasculitis-a single center experience and review of the literature. Clin. Nephrol. 64, 485-489 (2005).